ストックスクリーナーアプリを入手
4.7147
1.98%
-0.0953
前日終値:
$4.81
開ける：
$4.84
24時間の取引高:
23,123
Relative Volume:
0.27
時価総額：
$78.35M
収益：
-
当期純損益:
$-23.87M
株価収益率:
-0.2397
EPS:
-19.67
ネットキャッシュフロー:
$-47.63M
1週間 パフォーマンス:
+7.89%
1か月 パフォーマンス:
+20.89%
6か月 パフォーマンス:
+25.39%
1年 パフォーマンス:
+47.33%
1日の値動き範囲:
$4.70
$4.95
1週間の範囲:
$4.25
$5.047
52週間の値動き範囲:
$2.30
$5.047
Polypid Ltd Stock (PYPD) Company Profile
PYPD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
4.71 | 80.01M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.35 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.46 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.97 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.21 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | 開始されました | Roth Capital | Buy |
| 2025-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2021-09-14 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-07-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | 開始されました | Alliance Global Partners | Buy |
| 2020-07-21 | 開始されました | BMO Capital Markets | Outperform |
| 2020-07-21 | 開始されました | Barclays | Overweight |
| 2020-07-21 | 開始されました | Raymond James | Outperform |
すべてを表示
Polypid Ltd (PYPD) 最新ニュース
Aug Movers: Will PolyPid Ltd stock recover after earnings2025 Technical Overview & Low Drawdown Momentum Ideas - baoquankhu1.vn
PolyPid calls February 2026 extraordinary meeting to approve board chair compensation - MSN
Aug Sentiment: Is PolyPid Ltd stock technically oversoldJuly 2025 Institutional & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
PYPD: D-PLEX 100's phase 3 success paves the way for FDA submission and U.S. commercialization - TradingView — Track All Markets
Aug Catalysts: Will PolyPid Ltd stock return to pre crisis levels2025 Buyback Activity & Low Risk High Win Rate Picks - Bộ Nội Vụ
Why analysts remain bullish on PolyPid Ltd. stockQuarterly Risk Review & High Conviction Buy Zone Alerts - Улправда
Aug Big Picture: Can PolyPid Ltd. stock hit analyst price targetsJuly 2025 Earnings & Intraday High Probability Setup Alerts - Улправда
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Why PolyPid Ltd. stock could see breakout soonQuarterly Trade Review & Comprehensive Market Scan Insights - Улправда
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Polypid names medtech veteran Brooke Story as board chairman - marketscreener.com
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
PolyPid (PYPD) appoints medtech veteran Brooke Story as board chairman - Stock Titan
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets
Transcript : PolyPid Ltd.Special Call - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD) - TradingView — Track All Markets
PolyPid receives FDA support for D-PLEX100 NDA submission By Investing.com - Investing.com Australia
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA - FinancialContent
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com Nigeria
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 By Investing.com - Investing.com South Africa
PolyPid receives FDA support for D-PLEX100 NDA submission - Investing.com
PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission - marketscreener.com
Polypid announces positive FDA Pre-NDA meeting minutes - marketscreener.com
PolyPid Gains FDA Support for D-PLEX100 NDA Submission - TipRanks
PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission - TipRanks
PolyPid (NASDAQ: PYPD) highlights positive FDA pre-NDA minutes for D-PLEX100 NDA path - Stock Titan
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
How institutional buying supports PolyPid Ltd. stockExit Point & Expert Approved Momentum Ideas - Newser
PolyPid stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
PolyPid stock rating reiterated at Market Outperform by Citizens By Investing.com - Investing.com India
Polypid Ltd (PYPD) 財務データ
収益
当期純利益
現金流量
EPS
3.79%
1.90%
大文字化:
|
ボリューム (24 時間):